TrialCPT: pharmacometrics & systems pharmacology2017

Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis.

Xin Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.